期刊
JOURNAL OF NEUROIMMUNOLOGY
卷 299, 期 -, 页码 107-111出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2016.09.001
关键词
Encephalitis; Autoimmune encephalitis; Low-dose IL-2; Regulatory T cell
资金
- Seoul National University Hospital research fund [02-2016-0430, 25-2014-0040]
- National Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future Planning, Republic of Korea [2016R1C1B2011815]
- National Research Foundation of Korea [2016R1C1B2011815] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Low-dose interleukin-2 (IL-2) restores the balance of regulatory and effector T cells. We aimed to determine the feasibility of low-dose IL-2 as a treatment for refractory autoimmune encephalitis (AE). Ten patients who had received low-dose IL-2 were retrospectively identified. We observed an improvement in the modified Rankin Scale scores of six patients at the last follow-up compared with the scores at the initiation of low-dose IL-2 (p = 0.014). One patient experienced treatment-related grade 3 neutropenia. Overall, low-dose IL-2 is a feasible and relatively safe treatment for AE patients who are refractory to the first- and second-line immunotherapies. (C) 2016 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据